On Monday, PDL BioPharma Inc (NASDAQ:PDLI)’s shares inclined 0.16% to $6.45.
PDL BioPharma Inc (PDLI) will make presentations and take part in conferences with investors and analysts during the Jefferies 2015 Global Healthcare Conference in New York City, New York. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.
Limitation of Incorporation by Reference
In accordance with General Instruction B.2. of Form 8-K, this information, counting the Exhibit, is furnished following Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be revealed solely by Regulation FD.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.
RR Donnelley & Sons Co (NASDAQ:RRD)’s shares dropped -1.72% to $18.28.
RR Donnelley & Sons Co (RRD) declared that it has accomplished its formerly declared acquisition of Courier Corporation, one of America’s major book manufacturers in addition to a leader in content administration and customization in new and traditional media.
R.R. Donnelley & Sons Company provides integrated communications solutions to private and public sector clients in the United States and internationally. The company operates through Publishing and Retail Services, Variable Print, Planned Services, and International segments.
At the end of Monday’s trade, KKR & Co. L.P. (NYSE:KKR)‘s shares dipped -0.56% to $22.97.
Bayer AG has reached a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR & Co. L.P. (KKR) and the Panasonic Corporation. The total consideration for the transaction is EUR 1,022 million (JPY 138 billion). The sale will comprise the leading Contour™ portfolio of blood glucose monitoring meters and strips, in addition to other products such as Breeze™2, Elite™ and Microlet™ lancing devices. Closing of the transaction is subject to customary conditions, counting relevant antitrust clearance, and is predictable to occur in the first quarter of 2016.
Johannes Huth, Member and Head of KKR Europe, Africa and Middle East, and Hiro Hirano, Member and CEO of KKR Japan, said, “We are happy that Bayer Diabetes Care chose Panasonic Healthcare and KKR as the trusted partners for bringing the business to its next stage of development. This is another milestone in KKR’s track record of partnering with leading German and Japanese corporate and in growing top health care companies. Together, we will leverage our experience and network to create a global diabetes care solutions powerhouse in an effort to make this a transformational transaction for the diabetes care industry.”
Bayer’s Diabetes Care business is a technological leader in blood glucose monitoring systems, lancing devices and diabetes administration software. The business accounted for EUR 909 million in sales in 2014, with Contour™ being the principal product portfolio. The Contour™ portfolio comprises Contour™ Next, Contour™ Plus, Contour™ and Contour™ TS and is designed to meet the needs of all patients regardless of type of diabetes, stage of disease, or testing frequency. Other products comprise Breeze™2, Brio™, Entrust™, Elite™ and Microlet™ lancing devices.
KKR & Co. L.P. is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, administration buyouts, credit special situations, growth equity, mature, mezzanine, distressed, and middle market investments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.